Your browser doesn't support javascript.
loading
Vascular response following implantation of the third-generation drug-eluting resorbable coronary magnesium scaffold: an intravascular imaging analysis of the BIOMAG-I first-in-human study.
Seguchi, Masaru; Aytekin, Alp; Xhepa, Erion; Haude, Michael; Wlodarczak, Adrian; van der Schaaf, René J; Torzewski, Jan; Ferdinande, Bert; Escaned, Javier; Iglesias, Juan F; Bennett, Johan; Toth, Gabor G; Toelg, Ralph; Wiemer, Marcus; Olivecrona, Göran; Vermeersch, Paul; Waksman, Ron; Garcia-Garcia, Hector M; Joner, Michael.
Afiliación
  • Seguchi M; Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technical University Munich, Munich, Germany.
  • Aytekin A; Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technical University Munich, Munich, Germany.
  • Xhepa E; Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technical University Munich, Munich, Germany.
  • Haude M; Department of Cardiology, Rheinland Klinikum Neuss, Neuss, Germany.
  • Wlodarczak A; Department of Cardiology, Miedziowe Centrum Zdrowia S.A., Lubin, Poland.
  • van der Schaaf RJ; Department of Interventional Cardiology, OLVG, Amsterdam, the Netherlands.
  • Torzewski J; Cardiovascular Center Oberallgäu-Kempten, Kempten, Germany.
  • Ferdinande B; Department of Cardiology, Ziekenhuis Oost Limburg (ZOL), Genk, Belgium.
  • Escaned J; Division of Cardiology, Hospital Clínico San Carlos (IdISSC), Complutense University of Madrid, CIBERCV, Madrid, Spain.
  • Iglesias JF; Department of Cardiology, Geneva University Hospitals, Geneva, Switzerland.
  • Bennett J; Department of Cardiovascular Medicine, University Hospitals Leuven, Leuven, Belgium.
  • Toth GG; Division of Cardiology, Medical University Graz, Graz, Austria.
  • Toelg R; Cardiology Department, Heart Center Segeberger Kliniken, Bad Segeberg, Germany.
  • Wiemer M; Medical Faculty of the Christian-Albrechts-University of Kiel, Kiel, Germany.
  • Olivecrona G; Center for Cardiovascular and Diabetes Medicine, Asklepios Clinic Bad Oldesloe, Bad Oldesloe, Germany.
  • Vermeersch P; Department of Cardiology and Intensive Care, Johannes Wesling University Hospital, Ruhr University Bochum, Minden, Germany.
  • Waksman R; Department of Cardiology, Skåne University Hospital, Lund, Sweden.
  • Garcia-Garcia HM; Interventional Cardiology, ZNA Middelheim, Antwerp, Belgium.
  • Joner M; Interventional Cardiology, MedStar Washington Hospital Center, Washington, D.C., USA.
EuroIntervention ; 20(18): e1173-e1183, 2024 Sep 16.
Article en En | MEDLINE | ID: mdl-39279514
ABSTRACT

BACKGROUND:

The 12-month outcomes of BIOMAG-I - the first-in-human study investigating the third-generation drug-eluting resorbable magnesium scaffold (DREAMS 3G) - showed promising results regarding clinical outcomes and late lumen loss.

AIMS:

The current study aimed to investigate vascular healing parameters assessed by optical coherence tomography (OCT) and intravascular ultrasound (IVUS), focusing on strut visibility, vessel and scaffold areas, and neointimal growth patterns.

METHODS:

This is a BIOMAG-I substudy including patients with available serial OCT and IVUS data. We conducted a frame-based analysis of OCT findings in conjunction with IVUS-derived vessel and scaffold areas, evaluating the qualitative and quantitative aspects of vascular healing.

RESULTS:

Among the 116 patients enrolled in this trial, 56 patients treated with DREAMS 3G were included in the analysis. At 12 months, OCT imaging revealed that 99.0% of the struts were invisible, and no malapposed struts were depicted. While the vessel area showed no significant difference between the timepoints, the minimum lumen area significantly decreased from post-percutaneous coronary intervention to 6 months (6.88 mm2 to 4.75 mm2; p<0.0001), but no significant changes were observed between 6 and 12 months. Protruding neointimal tissue (PNT) - a unique neointimal presentation observed following resorbable magnesium scaffold implantation - was observed in 89.3% of the study patients at 12 months, and its area exhibited a 47.4% decrease from 6 to 12 months.

CONCLUSIONS:

This imaging substudy revealed that, at 12-month follow-up, virtually all struts of the DREAMS 3G scaffold became invisible, without evident malapposition. The vascular healing response to DREAMS 3G implantation also appeared favourable up to 12 months, which is indicated by advanced strut degradation and spontaneous regressing PNT between 6 and 12 months.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de la Arteria Coronaria / Ultrasonografía Intervencional / Vasos Coronarios / Implantes Absorbibles / Tomografía de Coherencia Óptica / Stents Liberadores de Fármacos / Intervención Coronaria Percutánea / Magnesio Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: EuroIntervention Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA / TERAPEUTICA Año: 2024 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Francia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de la Arteria Coronaria / Ultrasonografía Intervencional / Vasos Coronarios / Implantes Absorbibles / Tomografía de Coherencia Óptica / Stents Liberadores de Fármacos / Intervención Coronaria Percutánea / Magnesio Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: EuroIntervention Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA / TERAPEUTICA Año: 2024 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Francia